Cat. No. |
Product Name |
CAS No. |
Information |
PC-62560 |
AS 703569
|
871357-89-0 |
Cenisertib (AS 703569;R763) is a novel potent, orally available inhibitor of Aurora kinases, exhibits signifficant anti-proliferative activity against a wide range of tumor cells both in vitro and in vivo (A549 EC50=9 nM). |
PC-42409 |
Tozasertib
|
639089-54-6 |
Tozasertib (MK-0457, VX-680) is a highly potent, selective and reversible Aurora kinase inhibitor with Ki of 0.6, 18 and 4.6 nM for Aurora A, B and C, respectively. |
PC-49273 |
PF-03814735
|
942487-16-3 |
PF-03814735 is a potent, orally bioavailable, reversible inhibitor of both Aurora A and Aurora B kinases with IC50 values of 0.8 and 5 nM, respectively. |
PC-38795 |
PHA-680626
|
398493-74-8 |
PHA-680626 is a kinase inhibitor exhibiting strong inhibitory activity on both Bcr-Abl and Aurora kinases, also inhibits the formation of the Aurora-A/N-Myc complex. |
PC-73448 |
Tinengotinib
|
2230490-29-4 |
Tinengotinib (TT-00420) is a spectrum-selective multikinase inhibitor that targets cell proliferation, angiogenesis, and immunomodulatory pathways by inhibiting Aurora A/B and JAK involved in cytokine signalling, and RTKs involved in angiogenesis (FGFRs and VEGFRs). |
PC-73347 |
F114
|
|
F114 is a novel, first-in-class, dual aurora and lim kinase inhibitor with IC50 of 72 nM and 137 nM against Aurora-A and Limk1, respectively, F114 inhibits GBM proliferation and invasion. |
PC-72439 |
TAS-119
|
1453099-83-6 |
TAS-119 (TAS119) is a potent, selective, orally active inhibitor of Aurora A with IC50 of 1 nM. |